iQ&A Interactive Diabetes Intelligence Zone for SGLT2 Inhibitor-Based Management of T2D
The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes national and international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor.

The iQ&A platform stresses:

  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement

Program Medium
Internet-based program


Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period December 30, 2013 through December 30, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 154 segments, totaling 5 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

5.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in type 2 diabetes management.

Release Date

December 30, 2013

Expiration Date

December 30, 2015

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with or at risk for thrombosis.

This constituency of HCPs shall include the following audience:

  • Diabetologists
  • Endocrinologistss
  • Primary care physicians
  • Internal medicine specialists
  • Cardiologists
  • Diabetic nurse practitioners NPs
  • Related practitioners



Registration

Participation in this iQ&A interactive Medical Intelligence Zone for Diabetes Management is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

This activity is supported by an independent medical education grant from the Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners.




Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Vivian Fonseca, MD, FRCP - Program Chair
Professor of Medicine and Pharmacology
Tulis-Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology 
Tulane University Health Sciences Center
New Orleans, Louisiana

Research Support (To Tulane): Eli Lilly, Abbott, Reata, Asahi
Honoraria for Consulting and Lectures: Glaxo Smith Kline, Takeda, Novo Nordisk,sanofi-aventis, Eli Lilly, Pamlabs, Astra-Zeneca, Abbott, Bristol-Myers Squibb, Merck, Boehringer Ingelheim

 

Clifford J. Bailey, PhD, FRCP, FRCPath
UK Diabetes Research
Aston Pharmacy School School of Life
and Health Sciences Triangle
Aston University
Birmingham , UK

Advisor or consultant: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline;Merck Sharp & Dohme Corp.; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.

George Bakris, MD
Professor of Medicine
Director, Hypertension Center
University of Chicago Medical Center
Chicago, Illinois

Consultant: Takeda Pharmaceuticals North America, Inc.; Abbott Laboratories; CVRx; Johnson & Johnson Pharmaceutical
Research & Development, L.L.C.; Lilly USA, LLC; US Food and
Drug Administration
Speaker’s Bureau: Takeda Pharmaceuticals North America, Inc.
Grants: Forest Laboratories, Inc.

 

Anthony Barnett, MD, FRCP
Professor of Medicine
University of Birmingham
Honorary Consultant Physician and Clinical Director
Diabetes/Endocrinology/Weight Management
Heart of England NHS Foundation Trust
Birmingham, United Kingdom

Consultant: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Merck Sharp& Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi; Takeda Pharmaceuticals North America, Inc.
Speaker: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi; Takeda Pharmaceuticals North America, Inc.
Grant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi; Takeda Pharmaceuticals North America, Inc

 

John Buse, MD, PhD
Professor of Medicine
Director, Diabetes Care Center
Chief, Division of Endocrinology
Executive Associate Dean for Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Served as a director, officer, partner, employee, advisor, consultant, or trustee for:
Amylin Pharmaceutical, Inc. Andromeda, Bayhill Therapeutics, Biodel, Boehringer
Ingelheim, Catabasis, Diartis, Elcelyx, Eli Lilly and Co., Exsulin, GI Dynamics, Halozyme, Inc., Hoffman-LaRoche Inc., Johnson & Johnson, Lexicon, LipoScience, Medtronic MiniMed, Inc., Merck, Metabolon, Novan, Novo Nordisk Pharmaceuticals, Inc., Osiris Therapeutics, Inc., Orexigen, Pfizer, Inc., sanofi-aventis, Tolerex, Transition Therapeutics, TransPharma

 

Rafael Carmena, M.D, PhD, FACP, FRCP Edin
Professor of Internal Medicine and Endocrinology
University of Valencia
Chief of the Endocrine and Nutrition Service
University Hospital
Valencia, Spain

Nothing to disclose

 

Professor Bernard H. Charbonnel, MD
Professor of Endocrinology and Metabolic Diseases
University of Nantes
Nantes, France

Advisor/Consultant: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Eli Lilly and Company; Merck Sharpe & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.
Speaker: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Eli Lilly and Company; Merck Sharpe & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; sanofi-aventis; Takeda Pharmaceuticals North America, Inc

 

Jaime Davidson, MD, FACP, MACE
Clinical Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism
University of Texas Southwestern Medical School
Dallas, Texas

Consultant: Aspire Bariatrics, Inc., Allergan, Inc., AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., and sanofi-aventis U.S. LLC
Speaker's Bureau: LifeScan, Inc.
Consultant fees and Speaker's Bureau: Eli Lilly and Company and Novo Nordisk A/S.

Ralph A. DeFronzo, MD
Professor of Medicine
School of Medicine
Diabetes and Metabolic Disorders (DMD) Track
Diabetes Research Unit
Barter Research Unit, UTHSCSA
UTHSCSA Graduate School of Biomedical Sciences
San Antonio, Texas

Consultant: Amylin, Eli Lilly, Takeda, Bristol-Myers Squibb, Astra Zeneca, J&J, Novartis, Merck
Grants: Amylin, Eli Lilly, Takeda, Bristol- Myers Squibb

Robert Henry, MD
Chief, Center for Metabolic Research
Chief, VA Endocrinology & Metabolism
Professor of Medicine in Residence
University of California San Diego
San Diego, CA

Consultant: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ClinMet, Inc.; Daiichi Sankyo, Inc.; Elcelyx Therapeutics, Inc.; Lilly USA, LLC; Intarcia Theapeutics, Inc.; Isis Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Roche; Genentech, Inc.; Sanofi 
Grant/Research Support: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Lilly USA, LLC; Sanofi

 

Silvio E. Inzucchi, MD
Professor of Medicine (Endocrinology)
Clinical Director, Section of Endocrinology
Director, Yale Diabetes Center
Director, Endocrinology & Metabolism Fellowship
Director, Yale Affiliated Hospitals Program
New Haven, Connecticut USA

Consultant: Takeda, Amylin, Merck, Boehringer‐Ingelheim

 

Lawrence A. Leiter, MD, FRCP(C), FACP
Professor, Departments of Medicine and Nutritional Sciences
Head of the Division of Endocrinology and Metabolism
Director of the Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
University of Toronto
Toronto, Ontario CANADA

Consultant or speaker: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Lilly USA, LLC; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi.

 

Dr. Juris J. Meier, MD
St Josef-Hospital
Klinikum der Ruhr-Universität Bochum
Bochum, Germany

Nothing to disclose

 

Professor Paolo Pozzilli, MD
Professor of Diabetes and Clinical Research
Centre for Diabetes
Barts and The London School of Medicine & Dentistry
London, United Kingdom
Professor of Endocrinology & Metabolic Diseases
University Campus Bio-Medico
Rome, Italy

Nothing to disclose

 

Richard E. Pratley, MD
Director, Florida Hospital Diabetes Institute
Senior Scientist
Translational Research Institute for Metabolism and Diabetes
Professor, Sanford Burnham Medical Research Institute
Orlando, Florida

Consultant: Novartis Pharmaceuticals Corporation; Lilly USA, Inc; Eisai Inc.; Takeda Pharmaceuticals North America, Inc.; Novo Nordisk; Merck & Co., Inc.; MannKind Corporation; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Roche; Sanofi; GlaxoSmithKline; Lexicon Pharmaceuticals, Inc.
Grants/Research Support: Novartis Pharmaceuticals Corporation; Lilly USA, Inc; Takeda Pharmaceuticals North America, Inc.; Novo Nordisk; Merck & Co., Inc.; MannKind Corporation; Bristol-Myers Squibb Company; Roche; Sanofi; GlaxoSmithKline

 

Charles F. Shaefer Jr, MD, FACP
Assistant Clinical Professor of Medicine
Medical College of Georgia
Augusta, Georgia

Consultant: Sanofi-Aventis, BMS-AZ
Speaker's Bureau: Sanofi-Aventis, Amylin, BI/Lilly, BMS-AZ, Novartis

 

Mark E. Williams, M.D.
Clinical Investigator
Section on Clinical Research at Joslin
Senior Staff Physician at Joslin Clinic
Co-Director of Dialysis at Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School

Consultant: sanofi-aventis

 

Vincent Woo, MD
Endocrinology Section
Department of Internal Medicine
University of Manitoba
Health Sciences Centre Diabetes Research Group
Winnipeg, Canada

Nothing to disclose

 


Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.


Educational Objectives

Upon completion of this activity, participants will be able to:

  • Detail the epidemiology, scope of problem, risk assessment, target goals, and multiple interventions that currently are deployed for T2D and that have been shown to be helpful for glycemic regulation in T2D; and, discuss the impact of successful glycemic management of T2D on microvascular and macrovascular complications; and their impact on comprehensive cardiometabolic management of patients with T2D;
  • Evaluate advances in therapeutic strategies based on new mechanisms, involving SGLT2 inhibitors (encoded by the SLC5A2 gene), and their impact on glucose homeostasis; and, the effects these agents may have on cardiometabolic markers, including lipids, insulin resistance, intra-renal hemodynamics, inflammatory pathways, HA1c levels, glucose levels, and microvascular/macrovascular disease;
  • Evaluate the mechanisms underlying, and the potential clinical implications of, SGLT2 inhibition and its potential for shifting the glucose “reabsorption/excretion” threshold to the left, thereby introducing a physiological basis for reducing plasma glucose in patients with T2D; and, in which patient populations and for which clinical profiles, such mechanisms and metabolic effects may be of special benefit;
  • Discuss recent advances in our scientific and practical understanding of mechanisms of action of targeted agents that affect glucose reabsorption in the kidney, the scientific and clinical rationale for such agents, and how their actions can produce improvements in HA1c target levels and other goals identified by such national organizations as ADA and AACE; and, how they may be used as monotherapy or in combination therapy—i.e., in combination with one, two, or three other oral agents used for T2D;
  • Analyze the relationship between T2DM and atherosclerosis, and how emerging therapies might affect signaling and inflammatory signals, including cytokines, inflammation, and insulin resistance, and the vasculopathic cascade that characterizes T2DM and its adverse thrombovascular sequelae.


Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Disclaimer

Copyright © 2013 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © CMEducation Resources, LLC